Moreover, activation of GCN2 is not confined to EIF2AK inhibitors or RAFi; in the course of our work certain EGFR tyrosine kinase inhibitors including Erlotinib and Neratinib have also been shown to activate GCN2 in glioblastoma cell lines60. Here, EGFR is linked to glioblastoma.